IGC Pharma, Inc.

Where It Passes

Where It Falls Short

• Valuation0% pass✓ 1✗ 27▾

  No clean pass — all 13 investors flag at least one valuation criterion

  Price / 3-yr avg EPS

  ✗Graham<= 15x

  Price-to-Book Ratio2.3x

  ✗Graham<= 1.5x

  P/E x P/B

  ✗Graham<= 22.5

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  EBIT / Enterprise Value-36.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-36.7%, ROC=-215.4%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Price / EPS

  ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  Price / Book Value per Share2.3x

  ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)

  Valuation ReasonablenessOE Yield=-45.4%

  ✗MungerP/E < 25 or Owner Earnings Yield > 5%

  P/E or FCF YieldFCF Yield=-23.9%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  P/B or P/E vs. Historical AverageP/B=2.3x

  ✗MarksP/E < 15 or P/B < 2.0

  Discount to Intrinsic Value

  ✗Marks>= 20% below intrinsic value

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Price vs. Trailing Low100% of trailing low ($0.18)

  ✓Templeton<= 120% of trailing low (certified split-adjusted live window)

  Net income / market capitalization-34.68%; #4885/6340 (top 77.1%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Positive book equity / market capitalization+0.3166; #3623/6449 (top 56.2%)

  ✗AsnessTop 30% of eligible cross-section

  Price / Diluted EPS

  ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)

  (EPS CAGR % + Dividend Yield %) / P/E

  ✗Neff> 0.7 (Neff's published traditional edge)

  Price / Tangible Book Value per Share3.25x

  ✗SchlossP/TBV <= 1.00x (app cutoff)

  Book Value per Share Change-88.4%

  ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)

  Revenue / market capitalization+0.0619; #4513/5247 (top 86.0%)

  ✗OshaughnessyTop 10% of eligible cross-section

  (Operating cash flow - capex) / market capitalization-23.89%; #3581/4519 (top 79.2%)

  ✗OshaughnessyTop 10% of eligible cross-section

  Trailing six-month price return through the evaluation date-43.75%; #4944/6202 (top 79.7%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Cash Flow0% pass✓ 1✗ 11▾

  No clean pass — all 10 investors flag at least one cash flow criterion

  Free Cash Flow Proxy$-6.6M

  ✗BuffettPositive and growing

  FCF Positive and Growing$-4.9M

  ✗LynchPositive and growing

  Operating Cash Flow$-4.8M

  ✗PiotroskiCFO > 0

  (CFO / Total Assets) vs ROACFO/Assets=-54.82%, ROA=-81.42%

  ✓PiotroskiCFO/Assets > ROA

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  P/E or FCF YieldFCF Yield=-23.9%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  FCF Positive1/15 years FCF positive

  ✗MarksPositive FCF in majority of recent years

  (OCF - CapEx) / Market Cap-33.7%

  ✗Ackman>= 4%

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Positive Operating Cash Flow frequency1/15 years positive

  ✗SleepPositive OCF in >= 70% of available years

  Operating Cash Flow - Capital Expenditures$-4.9M

  ✗Neff> $0 (app proxy for a strong fundamental case)

  (Operating cash flow - capex) / market capitalization-23.89%; #3581/4519 (top 79.2%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Growth0% pass✓ 3✗ 10▾

  No clean pass — all 8 investors flag at least one growth criterion

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  Inventory Growth vs Revenue GrowthInv: -11.7% vs Rev: -5.5%

  ✓LynchInventory growth < Revenue growth

  EPS Growth Direction

  ✗DremanPositive over recent years

  EPS CAGR

  ✗Dreman> 5% annualized

  Positive Net Income Frequency0/15 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  3yr Median Revenue Growth47.6%

  ✓Ackman>= 5%

  Positive EPS Growth Frequency

  ✗AckmanPositive EPS growth in >= 3 of last 5 years

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Revenue growth vs. gross and operating margin trendgross margin 48.5% -> 48.7%, operating margin -1270.1% -> -585.8%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  5-year Revenue CAGR-20.8%

  ✗SleepCAGR > 7%

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized
• Efficiency0% pass✓ 1✗ 10▾

  No clean pass — all 8 investors flag at least one efficiency criterion

  Current Ratio0.42

  ✗Graham>= 2.0

  ROIC (3-5 yr avg)-84.8%

  ✗Buffett> 10%

  ROIC - WACC-94.8%

  ✗BuffettPositive (WACC = 10%)

  EBIT / (NWC + Net Fixed Assets)-215.4%

  ✗Greenblatt> 25%

  Current Ratio Change YoY1.58 -> 1.28

  ✗PiotroskiIncreased YoY

  Revenue / Total Assets Change YoY0.14x -> 0.15x

  ✓PiotroskiImproved YoY

  Current Assets / Current Liabilities0.42

  ✗Dreman> 1.5

  Return on Invested Capital-91.0%

  ✗Munger> 15%

  ROIC (high and growing)FY2022: ROIC=-60.7%; FY2023: ROIC=-103.7%; FY2024: ROIC=-91.0%

  ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each

  Reinvestment Rate x ROICN/A (non-positive net income)

  ✗AkreReinvestment Rate * ROIC > 10%

  ROIC (5-year)0/5 years above 12% (latest -91.0%)

  ✗SleepROIC > 12% in a majority of years
• Profitability6% pass✓ 4✗ 31▾

  15 of 16 flag IGC's profitability — Graham, Buffett, Lynch +12 more

  Positive EPS (10 years)0/20 years positive

  ✗GrahamPositive EPS every year for 10 years

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Net Income Positive (10+ years)0/20 years positive

  ✗BuffettPositive every year for 10+ years

  ROE (up to 5-year arithmetic mean)-91.4%

  ✗Buffett> 15% arithmetic mean (app rule)

  Operating Margin (10-yr trend)-585.8% (latest)

  ✗BuffettStable or rising over 10 years

  Free Cash Flow Proxy$-6.6M

  ✗BuffettPositive and growing

  Earnings Variance (10-yr CoV)

  ✗BuffettCoV < 0.3

  Retained Earnings Effectiveness

  ✗Buffett$1 retained -> > $1 market value created

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  ROE-112.5%

  ✗Lynch> 15%

  EBIT / Enterprise Value-36.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-36.7%, ROC=-215.4%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Net Income / Total Assets-81.42%

  ✗PiotroskiROA > 0

  ROA Change YoY-131.29% -> -81.42% (delta: +49.86%)

  ✓PiotroskiCurrent ROA > Prior ROA

  (CFO / Total Assets) vs ROACFO/Assets=-54.82%, ROA=-81.42%

  ✓PiotroskiCFO/Assets > ROA

  Gross Margin Change YoY54.5% -> 48.7%

  ✗PiotroskiImproved YoY

  Pre-Tax Income / Revenue-560.3%

  ✗Dreman>= 8%

  Net Income / Shareholders' Equity-112.5%

  ✗Dreman> 12%

  Margin of SafetyP/B=2.3x

  ✗PabraiP/B < 1.5 or P/E < 15

  Return on Equity-122.4% (3-yr avg)

  ✗AkreROE > 20% (3-year avg)

  Discount to Intrinsic Value

  ✗Marks>= 20% below intrinsic value

  Positive Net Income Frequency0/15 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  Operating Income / Revenue-585.8%

  ✗Ackman>= 15%

  Net Income / Shareholders Equity-112.5%

  ✗Ackman>= 15%

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Operating Margin Trend-1270.1% (2022) -> -585.8% (2024)

  ✓TempletonNon-negative operating-margin trend over 3 years

  Revenue growth vs. gross and operating margin trendgross margin 48.5% -> 48.7%, operating margin -1270.1% -> -585.8%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  Net income / market capitalization-34.68%; #4885/6340 (top 77.1%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Gross profit / total assets+7.08%; #2990/3702 (top 80.8%)

  ✗AsnessTop 30% of eligible cross-section

  Net income / positive book equity-112.51%; #4646/5226 (top 88.9%)

  ✗AsnessTop 30% of eligible cross-section

  Negative 5-year standard deviation of ROA-0.3503; #4698/5884 (top 79.8%)

  ✗AsnessTop 30% of eligible cross-section

  3-5 Year Diluted EPS CAGR

  ✗Neff7%-20% annualized

  Positive Diluted-EPS Years0/8 years positive

  ✗Schloss>= 70% positive over 5-10 observed years (app rule)
• Verdicts6% pass✓ 1✗ 15▾

  Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

  Overall verdict

  ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (3/7)✗GreenblattRank #2824✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2187/2370 (Top 92.3%))✗NeffFAIL (0/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
• Debt & Leverage50% pass✓ 9✗ 6▾

  6 of 12 pass — Buffett, Piotroski, Dreman +3 more object

  LT Debt vs Net Current AssetsLT Debt $0.1M vs NCA $0.6M

  ✓GrahamLT Debt <= Net Current Assets

  Debt/Equity & Interest CoverageD/E: 0.02, IC: -1489.2x

  ✗BuffettD/E < 0.5 AND Interest Coverage > 5x

  Total Debt / Equity0.13

  ✓Lynch< 0.33

  Cash - Long-term Debt$0.3M

  ✓LynchPositive preferred

  LT Debt / Total Assets Change1.38% -> 1.53%

  ✗PiotroskiDecreased YoY

  Current Assets / Current Liabilities0.42

  ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)

  Total Debt / Shareholders' Equity0.13

  ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x

  Debt Levels0.13

  ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3

  Interest Coverage & Debt/EBITDAIC=-1489.2x, D/EBITDA=N/A

  ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x

  Total Debt / Shareholders Equity0.13

  ✓Ackman<= 1.0

  Negative debt-to-equity (higher means less debt)-0.1337; #1434/4210 (top 34.1%)

  ✗AsnessTop 30% of eligible cross-section